Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...